- Home
- HEES vs GERN Comparison
HEES vs GERN Comparison
Compare HEES & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEES
- GERN
- Stock Information
- Founded
- HEES 1961
- GERN 1990
- Country
- HEES United States
- GERN United States
- Employees
- HEES N/A
- GERN N/A
- Industry
- HEES Misc Corporate Leasing Services
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- HEES Industrials
- GERN Health Care
- Exchange
- HEES Nasdaq
- GERN Nasdaq
- Market Cap
- HEES 2.1B
- GERN 2.5B
- IPO Year
- HEES 2006
- GERN 1996
- Fundamental
- Price
- HEES $56.68
- GERN $4.02
- Analyst Decision
- HEES Buy
- GERN Strong Buy
- Analyst Count
- HEES 6
- GERN 10
- Target Price
- HEES $61.25
- GERN $6.95
- AVG Volume (30 Days)
- HEES 295.6K
- GERN 10.0M
- Earning Date
- HEES 10-29-2024
- GERN 11-07-2024
- Dividend Yield
- HEES 1.95%
- GERN N/A
- EPS Growth
- HEES N/A
- GERN N/A
- EPS
- HEES 3.94
- GERN N/A
- Revenue
- HEES $1,518,307,000.00
- GERN $29,480,000.00
- Revenue This Year
- HEES $4.55
- GERN $30,930.80
- Revenue Next Year
- HEES $3.91
- GERN $315.72
- P/E Ratio
- HEES $14.36
- GERN N/A
- Revenue Growth
- HEES 5.69
- GERN 9199.68
- 52 Week Low
- HEES $40.92
- GERN $1.64
- 52 Week High
- HEES $66.18
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- HEES 54.79
- GERN 48.45
- Support Level
- HEES $54.51
- GERN $3.60
- Resistance Level
- HEES $60.66
- GERN $3.86
- Average True Range (ATR)
- HEES 1.83
- GERN 0.22
- MACD
- HEES -0.38
- GERN -0.00
- Stochastic Oscillator
- HEES 61.60
- GERN 46.67
About HEES H&E Equipment Services Inc.
H&E Equipment Services Inc is an integrated equipment services company. It is focused on heavy construction and industrial equipment. It rents, sells, and provides parts and services support for four core categories of equipment including hi-lift or aerial work platform equipment, cranes, earthmoving equipment, and industrial lift trucks. It engages in five principal business activities: equipment rentals; new equipment sales; sales of rental equipment; parts sales; and services. The majority of its revenue is derived from the equipment rentals segment.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.